TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01212731

Intervention type: RADIATION
Intervention: Photon treatment plans
Description: 10 of the 30 subjects on Cohort 1 will receive photon treatment plans.

Intervention type: RADIATION
Intervention: Proton Treatment Plans
Description: 20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.

Intervention type: BEHAVIORAL
Intervention: Neurocognitive evaluation
Description: Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.

Intervention type: BEHAVIORAL
Intervention: Neurocognitive evaluation
Description: Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.

Intervention type: DEVICE
Intervention: Advanced MRI imaging
Description: Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing

Intervention type: DEVICE
Intervention: Advanced MRI imaging
Description: Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
Study: NCT02612415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula
Description: A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure
Description: CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
Study: NCT00986154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban tosylate(DU-176b)
Description: edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin/unfractionated heparin
Description: LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight heparin/unfractionated heparin
Description: LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
Study: NCT02278731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training program
Description: Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training program
Description: Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
Study: NCT03726437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealConsent
Description: This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stress and Mood Management
Description: This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
Study: NCT03911089

Intervention type: OTHER
Group type: OTHER
Intervention: UCD Anamix Infant
Description: UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
Study: NCT05474261

Intervention type: PROCEDURE
Intervention: Valsalva maneuver
Description: Valsalva maneuver: increase intrabdominal pressure
Study: NCT02744625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher doses of vasopressor therapy for a MAP of 75 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lower doses of vasopressor therapy for a MAP of 65 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol for light sedation
Description: Propofol for light sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol for light sedation
Description: Propofol for light sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol for light sedation
Description: Propofol for light sedation
Study: NCT01890785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: Single dose of a 70 mg capsule on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: Single dose of a 70 mg capsule on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: Single dose of a 70 mg capsule on Day 1
Study: NCT01532349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for \> 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for \> 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
Study: NCT00012194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00613678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Strategy Training
Description: The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The health education program is based on educational materials from the Arthritis Foundation.
Study: NCT04318535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 500 mg
Description: Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 500 mg
Description: Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 500 mg
Description: Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 250 mg
Description: Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 250 mg
Description: Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 250 mg
Description: Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Griseofulvin 500 mg
Description: Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Griseofulvin 500 mg
Description: Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Griseofulvin 500 mg
Description: Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
Study: NCT00646087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine/Saline
Description: 0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
Study: NCT05061264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
Study: NCT01197079

Intervention type: OTHER
Intervention: Survey
Description: Self administered anonymous survey

Intervention type: OTHER
Intervention: Survey
Description: Self administered anonymous survey
Study: NCT03652311

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ThermoNeuroModulation TNM Device
Description: Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermoNeuroModulation TNM Device
Description: Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
Study: NCT01173848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
Study: NCT04044677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDSC-active
Description: 10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-sham
Description: 10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
Study: NCT03421197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPC-06 400 mg QD
Description: Tepilamide Fumarate 400 mg tablet once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPC-06 400 mg BID
Description: Tepilamide Fumarate tablets 400 mg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPC-06 600 mg
Description: Tepilamide Fumarate tablets 600 mg twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
Study: NCT03125668

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face counseling
Description: They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
Study: NCT01591278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Comparison of two different pulp dressing agents
Study: NCT01585415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
Study: NCT02095626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-301
Description: orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
Study: NCT01733186

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARTISTEM®
Study: NCT00962949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II infusion for 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II infusion for 1 hour
Study: NCT00864487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: HKI-272
Study: NCT01150513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-T
Description: four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP
Description: six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Study: NCT02127229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopist informed of cost per procedure
Description: Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
Study: NCT01073059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid and Ertapenem
Study: NCT00568776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: ELND005 matched placebo capsules for oral administration, bid for 78 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELND005
Description: ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELND005
Description: ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELND005
Description: ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
Study: NCT00246194

Intervention type: DRUG
Intervention: risperidone (RISPERDAL CONSTA)
Description: Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
Study: NCT03035825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly
Description: Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
Study: NCT00415142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saredutant (SR48968)
Description: oral administration (capsules)
Study: NCT03035825

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial saliva
Description: A non-edible oral lubricating gel for dry mouth patients
Study: NCT01598363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral, Day 1 and Day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral, Day 1 and Day 10
Study: NCT00014495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: bismuth Bi213 monoclonal antibody M195
Study: NCT00616837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Description: Outpatient consultation by help of telemedicine (video conference)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care in orthopaedic outpatient clinic
Description: Standard care in orthopedic outpatient clinic (usual care)
Study: NCT01580852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dead Sea water
Description: Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pool water
Description: Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
Study: NCT02109627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: 5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT03125668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face counseling
Description: They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
Study: NCT03448549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: adjuvant chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur，gimeracil and oteracil potassium
Description: adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeloda
Description: adjuvant chemotherapy